Miracles and the case for theism

I would like to thank Keith Parsons for reviving my interest in this topic, and Robert McKim, Patrick Maher, Hugh Chandler, Jordan Howard Sobel, and William Alston for helpful remarks concerning previous versions of this paper.     

Aggressive behavior inhibition by serotonin and quipazine injected into the amygdala in the rat

The effects on aggressive behavior, open-field activity, and pain threshold of bilateral microinjections of serotonin (20 micrograms) and quipazine (20 micrograms), the direct serotonergic receptor agonist, into the cortico-medial amygdala were investigated in Wistar rats. Both drugs significantly prolonged the attack latency in isolated killer rats (predatory aggression model), and suppressed the incidence of aggressive postures/attacks in shock-induced fighting test (affective aggression). The only difference in the open-field behavior was the lower number of central square entries in drug-treated compared to saline-injected rats. None of the substances produced any significant change in jump threshold. It is concluded that stimulation of serotonin receptors within the amygdala produces inhibition of affective and muricidal behavior in isolated rats. The effect does not seem to be dependent on changes in general activity and pain sensitivity.     

Frequency of neurologic-psychiatric findings in the late phase following minor and medium severe blunt craniocerebral injuries

The authors present a short review of the pertinent literature and report on their own neuropsychiatric findings following internal craniocerebral injuries, at the same time drawing attention to the necessity of psychological examination. Statistical comparisons with the international literature are complicated owing to the different classifications used for craniocerebral injuries.     

Clinical trial of contemnol tablets (lithium retard Spofa)

A report on the clinical testing of the lithium-retard medicament Contemnol (Spofa). It details the way lithium-retard treatment is objectively and subjectively superior to the earlier and still current general lithium treatment.